Sevoflurane-remifentanil EC50 (The 50% Effective Concentration) Values for LMA-Supreme Versus LMA ProSeal Insertion

PHASE4CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Sevoflurane
Interventions
DEVICE

laryngeal mask supreme

Sevoflurane was administered by facial mask with concomitant remifentanil administration (at an effect-site of 4 ng/ml). The LMAS was inserted according to the manufacturer's recommendations with the patient's head in the neutral position. After equilibrium the LMAS was inserted and secured according to the manufacturer's recommendations, without using muscle relaxants. A single measurement will be obtained from each patient. If the patient reacted with movement, a 1-2 mg/kg dose of Propofol was administered.

DEVICE

laryngeal mask proseal

Sevoflurane was administered by facial mask with concomitant remifentanil administration (at an effect-site of 4 ng/ml).The LMAP was inserted according to the manufacturer's recommendations with the patient's head in the neutral position. After equilibrium the LMAP was inserted and secured according to the manufacturer's recommendations, without using muscle relaxants. A single measurement will be obtained from each patient. If the patient reacted with movement, a 1-2 mg/kg dose of Propofol was administered.

Trial Locations (1)

28007

Servicio de Anestesia, Hospital General Universitario Gregorio Marañón, Madrid

All Listed Sponsors
lead

Hospital General Universitario Gregorio Marañon

OTHER

NCT03003377 - Sevoflurane-remifentanil EC50 (The 50% Effective Concentration) Values for LMA-Supreme Versus LMA ProSeal Insertion | Biotech Hunter | Biotech Hunter